Catalyst's New Drug Was Old News, Investors Say

Law360, New York (October 28, 2013, 2:07 PM EDT) -- A putative class of Catalyst Pharmaceutical Partners Inc. investors on Thursday accused the company in Florida federal court of inflating its stock price by misrepresenting its orphan drug Firdapse as new, when another company had been giving it away for decades.

Lead plaintiff Atul Kamar Sood accuses the drug company, which develops prescription drugs for rare neuromuscular and neurological diseases, of touting the development of the drug Firdapse — used to treat Lambert-Eaton myasthenic syndrome, an autoimmune disorder — while failing to mention that New Jersey-based...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Sood v. Catalyst Pharmaceutical Partners Inc. et al


Case Number

1:13-cv-23878

Court

Florida Southern

Nature of Suit

Securities/Commodities

Judge

Ursula Ungaro

Date Filed

October 25, 2013

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.